Last updated: May 20, 2026
Executive summary: Feldene (piroxicam) is an older, off-patent NSAID with limited contemporary US clinical-trial activity and constrained near-term commercial upside in most markets due to generic availability. Market value drivers are regional pricing, continued OTC-adjacent access pathways where permitted, and substitution to newer NSAID classes when formularies tighten. For exclusivity, the expected state is that relevant branded exclusivity has long expired, leaving generics as the default competitive baseline.
Is there an updated clinical trials pipeline for FELDENE (piroxicam) in 2024–2026?
Featured snippet: No sustained, brand-level global development pipeline is evident for FELDENE/pioxicam in 2024–2026. The drug is widely marketed as a generic NSAID, and current clinical-trial activity is typically investigator-led, small, or repositioning-focused rather than sponsor-led to support new regulatory exclusivity.
What types of studies still show up for piroxicam trials?
- Comparative efficacy and tolerability in musculoskeletal pain settings (common endpoints: pain scores, functional indices).
- Short-duration pharmacodynamic/PK studies (cyclooxygenase activity markers, formulation comparisons).
- Adjuvant or regimen studies where piroxicam is one component in standard-of-care NSAID strategies.
- Safety surveillance-type studies (GI and renal risk monitoring), usually not tied to new product approvals.
Why do sponsor-led FELDENE-specific trials appear limited?
- Brand economics: piroxicam is mature and generic.
- Regulatory incentives: without a novel active or new protected indication tied to enforceable patents/exclusivity, sponsors generally deprioritize costly late-stage programs.
Which companies market FELDENE (piroxicam) and what is the competitive landscape?
Featured snippet: Competitive pressure is primarily generic. Brand-level market share is typically capped to legacy accounts and select geographies.
How does generics competition typically shape pricing for piroxicam?
- Rapid erosion of branded pricing after first generic entries.
- Formulary substitution to the cheapest NSAID with adequate efficacy and acceptable GI risk.
- Private-label and multi-source supply in many markets.
What differentiates the remaining commercial offerings?
- Dose form and strength (tablets, capsules, dispersible formats where available).
- Packaging and labeling for specific indications and local prescribing norms.
- Supply continuity (less about differentiation from an IP standpoint and more about distribution strength).
What is the market size and demand outlook for piroxicam (FELDENE) by geography?
Featured snippet: Demand persists due to low-cost access to an effective NSAID, but growth is typically modest and driven by local market dynamics rather than brand-led expansion.
Key market drivers
- Burden of osteoarthritis and musculoskeletal pain.
- Continued clinician reliance for acute flare-ups where NSAIDs are standard-of-care.
- Generics availability keeps spend stable or slowly declining in value terms even if volume remains steady.
Key constraints
- Ongoing prescriber risk management around NSAID safety (GI, renal, cardiovascular).
- Substitution to COX-2 selective options and topical NSAIDs for tolerability.
- Payer pressure to lower-cost alternatives in NSAID baskets, which compresses margins further for any brand residual pricing.
How strong is the patent estate for FELDENE (piroxicam) in the US and EU?
Featured snippet: The FELDENE brand and piroxicam active substance are long past their core composition and first approval-era IP. The practical IP situation is that generic manufacturers can compete, with the principal constraint coming from any residual formulation or method-of-use patents in specific jurisdictions, if any exist.
What patent types still matter commercially for mature NSAIDs?
- Formulation patents: delayed-release, controlled-release matrices, or specific excipient systems.
- Method-of-use patents: dosing regimens for particular indications or patient populations.
- Crystallization/polymorph patents: less common for established drugs but can appear in later life-cycle filings.
Practical enforcement reality for FELDENE
For an older NSAID with generic dominance, even where later-life patents exist, they often affect only a narrow product configuration rather than the active substance itself. That limits barriers to entry unless the competitor must match a specific protected formulation or labeled regimen.
When does FELDENE (piroxicam) lose exclusivity and what does that mean for generics?
Featured snippet: Exclusivity associated with the original FELDENE brand has already expired. Generics operate as the baseline competition model.
US exclusivity mechanics for mature small molecules
- Brand exclusivity is generally tied to new drug application exclusivities and patent term for the reference drug. These periods are time-bound and typically expired for piroxicam.
- For current market access, the central question is not whether exclusivity still exists, but whether any later patents constrain specific formulations.
EU and UK practical effect
- Even with parallel national filings, piroxicam’s mature status means branded monopoly is no longer the market structure.
- Competition tends to be multi-source generic with limited brand differentiation.
What Orange Book status applies to piroxicam/FELDENE and how many patents are listed?
Featured snippet: Orange Book listings, where present, are expected to be for generic-applicable patents that no longer block entry broadly. For a mature NSAID, any remaining listed patents usually do not confer meaningful branded exclusivity.
What buyers and litigators should look for in the Orange Book
- Whether any listed patents cover an active ingredient versus only specific dosage forms.
- Whether patents are “expired” or near-expiry.
- Whether any listed patents were tied to specific labeling language that could support a method-of-use argument.
What Paragraph IV or generic-entry risks exist for FELDENE (piroxicam)?
Featured snippet: Paragraph IV risk is generally low for a drug this mature because US generic entry has largely already occurred. Any remaining risk would be tied to later-life patents that cover narrow formulations.
What would trigger renewed Paragraph IV relevance?
- A new formulation or new dosage form with different regulatory labeling.
- A later-life patent family granted that ties to a specific route or release profile.
- Reintroduction of a brand-like product under a new application.
How does piroxicam (FELDENE) compare with competing NSAIDs on efficacy, safety, and formulary position?
Featured snippet: Piroxicam competes within a crowded NSAID class. Its positioning is typically efficacy-for-cost, with GI/renal risk influencing clinician choice.
Typical comparative patterns
- Versus ibuprofen and naproxen: similar NSAID class efficacy, differing safety profiles and dosing convenience.
- Versus COX-2 selective agents: COX-2 products may win tolerability discussions for certain patient populations, depending on local payer rules.
- Versus topical NSAIDs: topical products can reduce systemic exposure where appropriate, pulling some use away from oral NSAIDs.
Formulary impact
- Formularies frequently prefer a short list of NSAIDs based on bulk purchasing and safety protocols.
- Piroxicam remains a contender when cost is the deciding factor or when clinicians have established familiarity.
What regulatory pathway applies to generic FELDENE (piroxicam) in the US and other major markets?
Featured snippet: Generics typically use ANDA pathways in the US based on pharmaceutically equivalent oral formulations.
US pathway
- ANDA for small molecules with bioequivalence to a reference listed drug.
- For mature products, approval frequently relies on bioequivalence rather than new clinical efficacy data.
Other major markets
- EU: national marketing authorizations and mutual recognition frameworks; generics follow established reference products.
- UK: MHRA authorization regimes with reference to bioequivalence and quality dossier requirements.
What manufacturing and IP barriers could still affect piroxicam supply and pricing?
Featured snippet: For mature NSAIDs, supply and quality systems matter more than IP, unless a protected formulation exists.
Primary operational risks
- API sourcing volatility.
- GMP compliance for solid oral manufacturing.
- Stability and dissolution performance in generic scale-up.
- Packaging and labeling compliance for branded-equivalent presentations.
Clinical trial activity: what would a “meaningful update” look like for FELDENE?
Featured snippet: A meaningful update would be a sponsor-led trial tied to an NDA supplement, new indication, or a protected new formulation likely to qualify for exclusivity.
Why most piroxicam trials do not change the market
- Most studies are small and do not support new labeling expansion.
- Without enforceable IP tied to the new data package, commercial impact stays limited.
Key Takeaways
- FELDENE (piroxicam) is a mature, generic NSAID. The market structure is multi-source competition with minimal brand-led exclusivity impact.
- Clinical-trial activity in 2024–2026 is likely limited and typically not sponsor-led late-stage development that would change regulatory status or IP.
- Commercial outlook is steady-to-flat in value terms in most markets, driven by low-cost access and substitution pressures within the NSAID class.
- Generic entry risks are generally low due to long-expired core exclusivity, with any residual risk dependent on narrow, later-life formulation or method patents in specific jurisdictions.
FAQs
- What are the most common current indications labeled for piroxicam products that compete with FELDENE?
- Are there any newer piroxicam formulations (e.g., modified release) that change market exclusivity?
- Do piroxicam generics face FDA bioequivalence challenges or dissolution profile disputes?
- Which NSAIDs most commonly substitute for piroxicam on formularies in Europe and the US?
- What safety monitoring protocols most affect continued prescribing of oral piroxicam?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed 2026-05-21).
- ClinicalTrials.gov. Search results for piroxicam and FELDENE. (accessed 2026-05-21).
- European Medicines Agency. Public assessment and product information for piroxicam-containing medicinal products. (accessed 2026-05-21).
